Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Low-Grade Glioma Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market size for low-grade glioma has seen robust growth in the recent past. The market is predicted to expand from $1.39 billion in 2024 to $1.47 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this historic growth include an uptick in brain tumor awareness, a rise in oncology-focused funding to stimulate research, a surge in orphan drug designations, telemedicine proliferation, and increased access to healthcare.
In the ensuing years, the market for low-grade gliomas is projected to experience robust growth, reaching$1.84 billion by 2029 and expanding at a compound annual growth rate (CAGR) of 5.7%. The anticipated growth within this period is linked to the growing elderly population, escalating healthcare spending, a rise in the detection of brain tumors, growing governmental initiatives, and an increment in the occurrence and prevalence of high-grade gliomas. Key trends forecasted in this time frame encompass breakthroughs in imaging technologies, the advancement of radiation therapies, the inception of new chemotherapy protocols, the broadening of clinical trials, and the incorporation of immunotherapy.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp
What External and Internal Drivers Are Contributing to the Growth of theLow-Grade Glioma Market?
The escalating cases of brain tumors are anticipated to drive the expansion of the low-grade glioma market. Brain tumors are unusual cellular growths in the brain or nearby areas, which can either be benign or malignant. The increase in brain tumor cases is attributed to factors like increased radiation exposure, environmental contaminants, genetic susceptibility, and aging. Low-grade glioma assists in managing brain tumors by employing modern diagnostic methods and targeted treatments like surgery, radiation, and chemotherapy. These treatments aid in slowing down the tumor’s growth, preserving neurological functions, and enhancing patient prognosis. Thus, prompt detection and personalized treatment strategies are essential in managing other brain tumors that exhibit similar growth characteristics. As an example, The Central Brain Tumor Registry of the United States (CBTRUS), a US-oriented nonprofit organization, reported in October 2023 that in 2022, the global incidence of primary malignant brain tumors was about 3.5 per 100,000, with higher rates in affluent countries (4.9 per 100,000) than in low-middle (2.4 per 100,000) and low-income countries. Hence, the increasing cases of brain tumors are fueling the growth of the low-grade glioma market.
What Segment Types Define the Low-Grade Glioma Market Structure?
The low-grade gliomamarket covered in this report is segmented –
1) By Drug Type: Trametinib; Dabrafenib; Ivosidenib; Mirdametinib
2) By Treatment: Surgery; Chemotherapy; Radiation
3) By Route Of Administration: Topical; Oral
4) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Low-Grade Glioma Market?
North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Low-Grade Glioma Market?
The focus of key players in the low-grade glioma market is largely on the incorporation of combined therapies and targeted therapy, including genetic alteration medications, in order to establish a competitive advantage as well as improve treatments for children with low-grade glioma. Drugs that alter genetics are targeted therapies meant to alter or curb specific genetic differences or anomalies in cells, aiding in the treatment of diseases like cancer by halting the avenues that prompt unchecked cell growth. For example, Day One Biopharmaceuticals, a biotech establishment from the US, introduced Tovorafenib (Ojemda) in May 2024, after obtaining fast-tracked approval from the FDA. This therapy, designed for children aged six months and older with non-removable or recurring low-grade glioma (LGG) bearing BRAF gene alterations, is a convenient oral treatment administered once a week. It provides a crucial option for pediatric LGG patients who previously had limited treatment choices.
View the full report here:
https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report
What Is the Definition of the Low-Grade Glioma Market?
Low-grade gliomas are a type of brain tumor that develops from glial cells, which provide support and insulation to nerve cells in the brain, characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still cause significant neurological symptoms and may require treatments.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21215
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model